Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca ...

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory ...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to ...
Forbes

Mortgage Calculator: Estimate Your Home Loan Payments

Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors' opinions or evaluations. Disclaimer: Calculator results and default inputs are ...
Forbes

Best Free Budgeting Apps In 2026: Compare Our Top Picks

Budgeting apps, many of which are cost-free for the basic version, track outgoing spend and make it easier to identify where cutbacks can be made. So whether you’re attempting to budget for the first ...